Quote | Super Quote
IPO   |   IPO News   |   Listed IPO Information   |   Hot Listed IPO
Stock Code   IPO News IPO Timetable
IPO Detail
06667 美因基因
Listing Date2022/06/22
Listing Price18.000
  • 11.380 +0.180 (+1.607%)    Sink Below Listing Price
  • 15-min delayed, last update: 24/03/2023 18:00
Subscription Result
  • Subscription Rate
  • Guarantee One Lot Size
    20 lot
  • One Lot Success Rate

Mega Genomics is a leading genetic testing platform company in China with a focus on consumer genetic testing and cancer screening services.

The Group recorded with an average of over 246,000 tests performed per month in 2021. According to Frost & Sullivan, it is the largest consumer genetic testing platform in China in terms of the cumulative number of tests administered. Also, it was the largest genetic testing platform for cancer screening in China as measured by the number of tests administered in 2020.

The Group is a genetic testing company in China with integrated capabilities that cover the full cycle of upstream, midstream and downstream segments. The upstream segment business involves technologies developed by in-house research and development team and cooperation with third-party partners. Its research and development efforts currently focus on the development of LDT services and IVD products. The midstream segment business encompasses an advanced and comprehensive genetic testing technology platform. Its current testing capacity is up to 50,000 tests per day, which is the largest in industry.

The downstream segment business encompasses an extensive sales and marketing network. As of December 31, 2021, it covered over 1,400 healthcare institutions in more than 340 cities in China, and health checkup centers accounted for approximately 57% of institutional customers.

MarketHong Kong (Main Board)
Business NatureHealth Care
Major Business AreaChina
Board Lot200
No. of Offer Shares11.96M shares
No. of International Offer Shares10.77M shares
No. of HK Offer Shares1.20M shares
Offer Price$18.00 - $22.00
Stock Code6667
Sponsor(s)China Securities (International) Corporate Finance Company Limited
Underwriter(s)China Securities (International) Corporate Finance Company Limited, China Merchants Securities (HK) Co., Limited, Zhongtai International Securities Limited, Futu Securities International (Hong Kong) Limited, Tiger Brokers (HK) Global Limited, Livermore Holdings Limited, Guotai Junan Securities (Hong Kong) Limited
Application PeriodJun 10 (Fri) - noon, Jun 15 (Wed)
Price Determination DateJun 15 (Wed)
Result Announcement DateOn or before Jun 21 (Tue)
Result Announcement DateOn or before Jun 21 (Tue)
Dealings in Shares commence onJun 22, 2022. (Wed)
Reallocation of Shares Offered
Times of HK Offer Shares Subscription15X - 50X50X - 100XOver 100X
% of total shares reallocated to HK Offer30%40%50%
Sales Statistics (HKD)
Offer Price$18.00 - $22.00
Capitalization4.30B - 5.30B
NAV / share ($)$4.29 - $4.48 (Unaudited pro forma adj NAV / share)
Use Of Proceeds
Assuming the offer price being at HKD 20.0, the net proceeds raised would be HKD 190.10M, of which
30% : Sales, marketing and commercialization of consumer genetic testing and cancer screening services and products.
25% : Invested in research and development of services and products
20% : Increasing or expanding testing capability and capacity
15% : Investing or acquiring attractive technology or testing related companies that are complementary and synergistic with existing businesses.
10% : Working capital
Related Document
Remark: The above information is referenced from the prospectus.
  All data is calculated from the non- exercise rights(if applicable).
IPO Calculator
Subscription --
Result Announcement --
Listing --
Offer Price︰--
Currency :
Listing Price :
Board Lot :
Admission Fee*
Subscribing Lot :
Subscribing Fee :

Subscribing Amount :
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2023 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.